Although some studies have predicted the immune efficacy of breast cancer patients through TMB, PD-L1 expression, tumor-infiltrating lymphocyte, or mismatch repair, there is still a big gap between them and their actual clinical application [9, 42]. Here, CD274 is linked to neoplasm.